DE60035523D1 - Optimierte minigene und dadurch kodierte peptide - Google Patents
Optimierte minigene und dadurch kodierte peptideInfo
- Publication number
- DE60035523D1 DE60035523D1 DE60035523T DE60035523T DE60035523D1 DE 60035523 D1 DE60035523 D1 DE 60035523D1 DE 60035523 T DE60035523 T DE 60035523T DE 60035523 T DE60035523 T DE 60035523T DE 60035523 D1 DE60035523 D1 DE 60035523D1
- Authority
- DE
- Germany
- Prior art keywords
- encoded peptides
- vaccines
- optimized
- minigenes
- encoded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 229960005486 vaccine Drugs 0.000 abstract 3
- 230000005847 immunogenicity Effects 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6045—RNA rev transcr viruses
- C12N2810/6054—Retroviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17339099P | 1999-12-28 | 1999-12-28 | |
US173390P | 1999-12-28 | ||
PCT/US2000/035568 WO2001047541A1 (en) | 1999-12-28 | 2000-12-28 | Optimized minigenes and peptides encoded thereby |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60035523D1 true DE60035523D1 (de) | 2007-08-23 |
DE60035523T2 DE60035523T2 (de) | 2008-03-20 |
Family
ID=22631795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60035523T Expired - Lifetime DE60035523T2 (de) | 1999-12-28 | 2000-12-28 | Optimierte minigene und dadurch kodierte peptide |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1242108B1 (de) |
JP (2) | JP2004512815A (de) |
KR (1) | KR100838507B1 (de) |
CN (1) | CN1437476A (de) |
AT (1) | ATE366582T1 (de) |
AU (1) | AU780064B2 (de) |
BR (1) | BR0017052B1 (de) |
CA (1) | CA2394748A1 (de) |
DE (1) | DE60035523T2 (de) |
DK (1) | DK1242108T3 (de) |
ES (1) | ES2288885T3 (de) |
HK (1) | HK1048068B (de) |
MX (1) | MXPA02006554A (de) |
WO (1) | WO2001047541A1 (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7462354B2 (en) * | 1999-12-28 | 2008-12-09 | Pharmexa Inc. | Method and system for optimizing minigenes and peptides encoded thereby |
AU2002950183A0 (en) * | 2002-07-12 | 2002-09-12 | The Council Of The Queensland Institute Of Medical Research | Expression of hydrophobic proteins |
EP1578432A4 (de) * | 2002-10-03 | 2008-07-30 | Epimmune Inc | Hla-bindende peptide und deren anwendungen |
KR20050083719A (ko) * | 2002-10-03 | 2005-08-26 | 에피뮨 인코포레이티드 | 최적화된 멀티-에피토프 구성체 및 이의 용도 |
DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
WO2005047483A2 (en) * | 2003-11-12 | 2005-05-26 | Medical Research Council | Renta: an hiv immunogen and uses thereof |
DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
EP2023952B1 (de) * | 2006-05-18 | 2015-07-15 | Epimmune Inc. | Induktion von immunreaktionen auf das influenzavirus mithilfe von polypepitd- und nukleinsäure-zusammensetzungen |
US9249187B2 (en) | 2009-01-28 | 2016-02-02 | Epimmune Inc. | Pan-DR binding polypeptides and uses thereof |
GB0905519D0 (en) * | 2009-03-31 | 2009-05-13 | Biofortuna Ltd | Assay method and device |
WO2012159754A2 (en) | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
WO2014059489A1 (en) | 2012-10-19 | 2014-04-24 | The Council Of The Queensland Institute Of Medical Research | Improved human herpesvirus immunotherapy |
EP2925348B1 (de) | 2012-11-28 | 2019-03-06 | BioNTech RNA Pharmaceuticals GmbH | Individualisierte impfstoffe gegen krebs |
WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
WO2016045732A1 (en) | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
WO2016128060A1 (en) | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
CN105254719B (zh) * | 2015-10-21 | 2018-07-13 | 黑龙江八一农垦大学 | 金黄色葡萄球菌trap蛋白的cd4+t细胞表位鉴定及其重组表位疫苗 |
EP3744847A4 (de) * | 2018-01-22 | 2021-12-08 | Japan as Represented by The Director-General of National Institute of Infectious Diseases | Selektives cd8-positives t-zellinduzierendes impfstoffantigen |
WO2019226941A1 (en) * | 2018-05-23 | 2019-11-28 | Gritstone Oncology, Inc. | Shared antigens |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2195642A1 (en) * | 1994-07-27 | 1996-02-08 | Andreas Suhrbier | Polyepitope vaccines |
ATE244891T1 (de) * | 1996-04-26 | 2003-07-15 | Univ Leiden | Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope |
DK0935662T3 (da) * | 1996-05-24 | 2006-03-06 | Chiron Corp | Fusionsprotein med multiple epitoper |
GB9711957D0 (en) * | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
GB9808932D0 (en) * | 1998-04-27 | 1998-06-24 | Chiron Spa | Polyepitope carrier protein |
CA2331846C (en) * | 1998-05-13 | 2010-01-12 | Epimmune Inc. | Expression vectors for stimulating an immune response and methods of using the same |
-
2000
- 2000-12-28 AU AU26075/01A patent/AU780064B2/en not_active Ceased
- 2000-12-28 DK DK00989585T patent/DK1242108T3/da active
- 2000-12-28 BR BRPI0017052-6B1A patent/BR0017052B1/pt not_active IP Right Cessation
- 2000-12-28 JP JP2001548133A patent/JP2004512815A/ja active Pending
- 2000-12-28 KR KR1020027008507A patent/KR100838507B1/ko not_active IP Right Cessation
- 2000-12-28 ES ES00989585T patent/ES2288885T3/es not_active Expired - Lifetime
- 2000-12-28 MX MXPA02006554A patent/MXPA02006554A/es not_active Application Discontinuation
- 2000-12-28 WO PCT/US2000/035568 patent/WO2001047541A1/en active IP Right Grant
- 2000-12-28 EP EP00989585A patent/EP1242108B1/de not_active Expired - Lifetime
- 2000-12-28 DE DE60035523T patent/DE60035523T2/de not_active Expired - Lifetime
- 2000-12-28 CA CA002394748A patent/CA2394748A1/en not_active Abandoned
- 2000-12-28 AT AT00989585T patent/ATE366582T1/de active
- 2000-12-28 CN CN00819182A patent/CN1437476A/zh active Pending
-
2003
- 2003-01-08 HK HK03100192.3A patent/HK1048068B/zh not_active IP Right Cessation
-
2011
- 2011-03-14 JP JP2011056001A patent/JP5628716B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DK1242108T3 (da) | 2007-11-12 |
JP2011168592A (ja) | 2011-09-01 |
KR20020084424A (ko) | 2002-11-07 |
AU2607501A (en) | 2001-07-09 |
EP1242108B1 (de) | 2007-07-11 |
EP1242108A4 (de) | 2005-11-02 |
KR100838507B1 (ko) | 2008-06-17 |
CN1437476A (zh) | 2003-08-20 |
HK1048068B (zh) | 2008-02-22 |
MXPA02006554A (es) | 2003-09-22 |
BR0017052A (pt) | 2006-03-01 |
AU780064B2 (en) | 2005-02-24 |
ES2288885T3 (es) | 2008-02-01 |
JP2004512815A (ja) | 2004-04-30 |
DE60035523T2 (de) | 2008-03-20 |
CA2394748A1 (en) | 2001-07-05 |
BR0017052B1 (pt) | 2013-12-24 |
WO2001047541A1 (en) | 2001-07-05 |
HK1048068A1 (en) | 2003-03-21 |
JP5628716B2 (ja) | 2014-11-19 |
EP1242108A1 (de) | 2002-09-25 |
ATE366582T1 (de) | 2007-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60035523D1 (de) | Optimierte minigene und dadurch kodierte peptide | |
CY1119106T1 (el) | Αντισωματα εναντι masp-2 | |
DE60005953D1 (de) | Stapelbare statische mischelemente | |
AU2002302255A1 (en) | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases | |
CY1116149T1 (el) | Αντισωματα anti-tnf, συνθεσεις, μεθοδοι και χρησεις αυτων | |
AU2003296330A8 (en) | Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions | |
MXPA02005576A (es) | Vacuna para la prevencion y tratamiento de la enfermedad de alzheimer y otras enfermedades relacionadas con amiloides. | |
WO2003104273A3 (en) | THERAPEUTIC EPITOPES AND THEIR USES | |
YU9404A (sh) | Multimerna, usmerena kontrastna sredstva na bazi peptida | |
DE69435075D1 (de) | , die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten | |
IL210378A0 (en) | Tumor associated antigen, peptides thereof, and use of same as ati-tumor vaccines | |
YU9403A (sh) | Anti-dualna antitela integrina, kompozicije, postupci i primene | |
DE60143292D1 (de) | Varianten des menschlichen Koagulationsfaktors VII | |
BR0306905A (pt) | Vacinas de flavivìrus | |
WO2004031210A3 (en) | Optimized multi-epitope constructs and uses thereof | |
DK1290160T3 (da) | Humane Pellino-polypeptider | |
WO2004076614A3 (de) | Humane nukleinsäuresequenzen aus prostatakarzinomen | |
ATE360642T1 (de) | Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4 | |
ATE466879T1 (de) | 5t4-antigen-peptidepitope der mhc klasse ii | |
WO2005033265A3 (en) | Optimized multi-epitope constructs and uses thereof | |
EP1842549A3 (de) | Optimierte Minigene und mit diesen kodierte Peptide | |
ATE328082T1 (de) | Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen | |
WO2004053117A3 (en) | Serine protease | |
EP1329504A4 (de) | Nukleinsäure eines neuen menschlichen kinesin-assoziierten gens, von der nukleinsäure kodiertes protein, peptidfragment davon sowie die nukleinsäure und ähnliches enthaltende antikrebsmittel | |
AU2002360062A1 (en) | Tumour peptide antigen derived from the human cd19 protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |